Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Thalidomide may
stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if
interferon alfa is more effective with or without thalidomide in treating metastatic kidney
cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of interferon alfa with or
without thalidomide in treating patients who have metastatic kidney cancer.